Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing cellular immunotherapies. It designs new treatments for various forms of cancer, including both hematological cancers and solid tumors. The company offers CAR-T and CAR-NK cell therapies which are an approach in which a patient’s or donor’s T cells or NK cells, respectively, are genetically modified to carry chimeric antigen receptors, or CARs.